In vivo therapy of neoplastic meningitis with methotrexate and 5-[125I]iodo-2'-deoxyuridine

Acta Oncologica

Volumn 39, Issue 6, 2000, Pages 731-737

  Kassis, A I ^a   Dahman, B A ^a   Adelstein, S J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDOXURIDINE I 125; METHOTREXATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BRAIN TUMOR; CELL LEVEL; DRUG EFFICACY; MENINGITIS; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

ANIMALS; ELECTRONS; HUMANS; IDOXURIDINE; INJECTIONS, SPINAL; IODINE RADIOISOTOPES; MENINGITIS; METHOTREXATE; NUCLEIC ACID SYNTHESIS INHIBITORS; PARALYSIS; RADIOPHARMACEUTICALS; RATS; RATS, NUDE; RHABDOMYOSARCOMA; S PHASE; SPINAL CORD; TISSUE DISTRIBUTION;

EID: 0033712605     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600750063802     Document Type: Article

References (37)

1. Neoplastic meningitis
2. Neurologic complications of systemic cancer
3. Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases
4. Natural history of central nervous system acute leukemia in adults
5. Radiation treatment for medulloblastoma: A 21-year review
6. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis
7. Treatment of meningeal neoplasms
8. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate
9. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients
10. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia
11. Cerebellar degeneration caused by high-dose cytosine arabinoside: A clinicopathological study
12. Incorporation of 5-iodouracil labelled with iodine-131 into the deoxyribonucleic acid of human leukaemic leucocytes following in vivo administration of 5-iododeoxyuridine labelled with iodine-131
13. 125I in mammalian cells
14. Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2'-deoxyuridylate
15. Cytotoxic mechanisms of folate antagonists
16. Antineoplastic effect of iodine-125-labelled iododeoxyuridine
17. 123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model
18. Radiolabeled nucleoside analogs in cancer diagnosis and therapy
19. 125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases
20. 125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats
21. Kit formulation for the preparation of radiolabeled iododeoxyuridine by demetallation
22. 125IUdR in mammalian cells: Implications of localized energy deposition by Auger processes
23. Intracellular localisation of Auger electron emitters: Biophysical dosimetry
24. Dosimerry of Auger emitters: Physical and phenomenological approaches
25. 125I
26. Indirect mechanisms contribute to biological effects produced by decay of DNAincorporated iodine-125 in mammalian cells in vitro: Doublestrand breaks
27. 131iodine
28. 125IUdR in cultured mouse BP8 tumour cells
29. The radiotoxicity of iodine-125 in mammalian cells. I. Effects on the survival curve of radioiodine incorporated into DNA
30. 3H: Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia
31. 3HTdR
32. 125I-UdR in cultured mammalian cells
33. Positional effects of Auger decays in mammalian cells in culture
34. 123I: The use of the Auger effect as a biological probe at the nanometre level
35. Radionuclide toxicity in cultured mammalian cells: Elucidation of the primary site for radiation-induced division delay
36. 123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer
37. 123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer